Neuronetics, Inc. (NASDAQ:STIM) CEO Sells $23,063.25 in Stock

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith J. Sullivan sold 12,075 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $1.91, for a total value of $23,063.25. Following the transaction, the chief executive officer now owns 1,360,203 shares in the company, valued at approximately $2,597,987.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neuronetics Stock Performance

Shares of STIM traded down $0.10 during mid-day trading on Thursday, hitting $1.90. The company’s stock had a trading volume of 140,122 shares, compared to its average volume of 168,938. Neuronetics, Inc. has a one year low of $1.03 and a one year high of $5.07. The company has a debt-to-equity ratio of 2.15, a quick ratio of 5.18 and a current ratio of 5.65. The firm has a market capitalization of $57 million, a PE ratio of -1.98 and a beta of 2.32. The stock’s 50-day moving average is $2.03 and its two-hundred day moving average is $3.06.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.06. Neuronetics had a negative return on equity of 75.84% and a negative net margin of 37.61%. The company had revenue of $17.42 million during the quarter, compared to analysts’ expectations of $17.10 million. As a group, sell-side analysts anticipate that Neuronetics, Inc. will post -0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, William Blair raised Neuronetics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, May 14th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Worth Venture Partners LLC bought a new position in Neuronetics in the fourth quarter worth $30,000. SG Americas Securities LLC bought a new position in Neuronetics in the first quarter worth $62,000. Fielder Capital Group LLC bought a new position in Neuronetics in the fourth quarter worth $66,000. FNY Investment Advisers LLC bought a new position in Neuronetics in the fourth quarter worth $87,000. Finally, FourWorld Capital Management LLC bought a new position in Neuronetics in the first quarter worth $171,000. 53.59% of the stock is owned by institutional investors.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.